ReviewFrontiers in immunology2026
Multiple sclerosis and the limits of classical autoimmune theory.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concepts of autoimmune disease have traditionally emphasized genetic susceptibility, antigen-specific immune activation, and inflammation as linear drivers of tissue injury and clinical symptoms. While this framework has been highly successful in explaining disease initiation and guiding the development of immunomodulatory therapies, accumulating evidence indicates important limitations in its capacity to account for long-term disease outcomes. In this review, we use multiple sclerosis (MS) as an illustrative case through which autoimmune theory can be critically examined. MS provides strong support for immune-mediated mechanisms in early disease, yet it also shows that neurodegeneration and disability accumulation often become uncoupled from overt inflammatory activity. These observations challenge linear models and sustained coupling between immune activity, tissue injury, and clinical progression. We use this gap between theoretical expectations and observed disease patterns to examine broader conceptual issues relevant to autoimmune and immune-mediated diseases, particularly the need to distinguish between mechanisms of susceptibility, inflammatory activity, and progressive worsening, and to incorporate temporal dynamics, interactions, and tissue-specific responses into explanatory models. We argue that the main contribution of MS lies not in serving as a generalizable model, but in clarifying the scope and limits of autoimmune theory and in underscoring the importance of theoretical refinement for organizing increasingly complex empirical evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.